Back
HFA Premium Access

Short-term changes in hemoglobin and changes in functional status, quality of life, and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction

Session: Chronic heart failure - pharmacotherapy 5
Topic: Pharmacotherapy
Speaker: Miss M. Amiguet Comins (Castellon de la Plana, ES)
Event: Heart Failure 2023

Congress Presentation

About the speaker

Miss Martina Amiguet Comins

General University Hospital of Castellon, Castellon de la Plana (Spain)
0 follower

5 more presentations in this session

Sodium-glucose cotransporter 2 inhibitors in patients with transthyretin amyloid cardiomyopathy - results from a patient series

Speaker: Doctor J. Brito (Lisbon, PT)

Access
Abstract
Slides
Thumbnail

Trace element equilibrium in acute heart failure and the effect of empagliflozin

Speaker: Assistant Professor N. Bomer (Groningen, NL)

Access
Abstract
Slides
Thumbnail

Efficacy and safety of sacubitril-valsartan in heart failure with reduced ejection fraction in end-stage renal patients.

Speaker: Doctor R. Rascon Sabido (Veracruz, MX)

Access
Abstract
Slides
Thumbnail

Cost-utility analysis and eligibility of dapagliflozin for patients with heart failure across the whole spectrum of ejection fraction

Speaker: Doctor J. Youn (Seoul, KR)

Access
Abstract
Slides
Thumbnail

REALM-DCM: a phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 (PF-07265803) in patients with symptomatic LMNA-related dilated cardiomyopathy

Speaker: Doctor R. Barriales-Villa (Coruna, A, ES)

Access
Abstract
Slides
Thumbnail

Access the full session

Chronic heart failure - pharmacotherapy 5

Speakers: Miss M. Amiguet Comins, Doctor J. Brito, Assistant Professor N. Bomer, Doctor R. Rascon Sabido, Doctor J. Youn...
Access
Thumbnail

About the event

Image

Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb